Hexobarbital
A short-acting barbiturate that was used as an intravenous anesthetic for induction of general anesthesia and for short surgical procedures. It produces rapid unconsciousness by enhancing GABA-mediated inhibition in the central nervous system. It has largely been replaced by safer intravenous anesthetic agents such as propofol.
Molecular Weight
236.2700 g/mol
LogP
1.50
TPSA
66.50 Ų
Lipinski RO5
Pass
Mechanism of Action
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
2D Structure
Cite this structure
Embed this structure
SMILES
CN1C(=O)NC(=O)C(C)(C2=CCCCC2)C1=O
InChI
InChI=1S/C12H16N2O3/c1-12(8-6-4-3-5-7-8)9(15)13-11(17)14(2)10(12)16/h6H,3-5,7H2,1-2H3,(H,13,15,17)
Molecular Formula
C12H16N2O3
HBD / HBA
1 / 3
Rotatable Bonds
1
Heavy Atoms
17
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Frequently Asked Questions
A short-acting barbiturate that was used as an intravenous anesthetic for induction of general anesthesia and for short surgical procedures. It produces rapid unconsciousness by enhancing GABA-mediated inhibition in the central nervous system. It has largely been replaced by safer intravenous anesthetic agents such as propofol.
Selectively blocks angiotensin II type 1 (AT1) receptors, preventing the vasoconstrictive and aldosterone-secreting effects of angiotensin II. This results in vasodilation, reduced sodium retention, and decreased blood pressure.
Yes, Hexobarbital is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL7728. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 3608. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hexobarbital"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hexobarbital/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hexobarbital/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hexobarbital/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hexobarbital"></drugfyi-drug>